Respiratorius AB (publ) (XSAT:RESP)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.375
+0.025 (1.85%)
At close: Mar 23, 2026
Market Cap10.87M -65.9%
Revenue (ttm)n/a
Net Income-6.95M
EPS-1.17
Shares Out7.90M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume18,379
Average Volume14,184
Open1.325
Previous Close1.350
Day's Range1.320 - 1.375
52-Week Range1.190 - 10.500
Beta1.69
RSI48.56
Earnings DateMay 19, 2026

About Respiratorius AB

Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. The company’s products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1998
Employees 0
Stock Exchange Spotlight Stock Market
Ticker Symbol RESP
Full Company Profile

Financial Performance

Financial Statements